Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Wit, G. Ardine De

  • Google
  • 1
  • 10
  • 0

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (1/1 displayed)

  • 2020Multi-use disease modelscitations

Places of action

Chart of shared publication
Wang, Junfeng
1 / 1 shared
Pouwels, Xavier
1 / 1 shared
Ramaekers, Bram L. T.
1 / 1 shared
Frederix, Geert
1 / 1 shared
Hoogenveen, Rudolf T.
1 / 1 shared
Feenstra, Talitha
1 / 1 shared
Koffijberg, Erik
1 / 1 shared
Giessen, Anoukh Van
1 / 1 shared
Joore, Manuela
1 / 3 shared
Li, Xinyu
1 / 2 shared
Chart of publication period
2020

Co-Authors (by relevance)

  • Wang, Junfeng
  • Pouwels, Xavier
  • Ramaekers, Bram L. T.
  • Frederix, Geert
  • Hoogenveen, Rudolf T.
  • Feenstra, Talitha
  • Koffijberg, Erik
  • Giessen, Anoukh Van
  • Joore, Manuela
  • Li, Xinyu
OrganizationsLocationPeople

report

Multi-use disease models

  • Wang, Junfeng
  • Pouwels, Xavier
  • Ramaekers, Bram L. T.
  • Frederix, Geert
  • Hoogenveen, Rudolf T.
  • Feenstra, Talitha
  • Wit, G. Ardine De
  • Koffijberg, Erik
  • Giessen, Anoukh Van
  • Joore, Manuela
  • Li, Xinyu
Abstract

br/>The National Health Care Institute (hereinafter referred to as ZIN) advises the Minister of Health, Welfare and Sport (VWS) on a variety of topics, including reimbursements for medicines and other treatments in the mandatory health insurance package. For this purpose, among other things, ZIN uses dossiers from pharmaceutical companies, in which they estimate the health benefits and costs based on decision models. <br/><br/>These decision models are used to examine whether medicines and other treatments improve the health of individuals in the long term. For example, they calculate how better blood glucose levels in people with diabetes translate to less complications, such as cardiovascular diseases and amputations. The models incorporate the costs of the medicine, but also the savings made because the medicine reduces the likelihood of complications and the resulting high treatment costs. <br/><br/>ZIN is currently assessing decision models dossier by dossier, with a different decision model being used for almost every medicine or treatment. Therefore, it is difficult to compare the effects of a number of medicines for the same disease. ZIN also spends a lot of time testing the quality of each decision model. It would be better to have a single model for each disease, or multi-use models, as such models meant for repeated use might be called. This would enable those involved to make better and more consistent decisions. <br/><br/>RIVM and the Universities of Twente, Maastricht, Groningen and Utrecht have carried out a study into how ZIN could work with multi-use models. This report will assist ZIN in making the decision of whether to switch to multi-use models and, if so, how. By way of case study, RIVM has also created a multi-use model for diabetes. <br/><br/>RIVM and its partners have developed five business cases for working with multi-use models and described their advantages and disadvantages. The roles and responsibilities of the parties involved, i.e. ZIN, other research institutes, academic groups, and consultancy bureaus, vary in these options. Issues discussed include ownership of the model, who is responsible for the maintenance and storage of results and who is accountable if mistakes are made. Other issues discussed concern the model methods, among others what the model must be able to do and how flexible it has to be for adaptation.

Topics
  • impedance spectroscopy
  • laser emission spectroscopy